Inovio Pharmaceuticals (INO) Receives Media Impact Rating of 0.19

Media coverage about Inovio Pharmaceuticals (NASDAQ:INO) has trended somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Inovio Pharmaceuticals earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.398375206543 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news articles that may have impacted Accern’s analysis:

INO has been the subject of several analyst reports. Aegis restated a “buy” rating and set a $14.00 target price on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Citigroup Inc. initiated coverage on Inovio Pharmaceuticals in a research report on Friday, October 6th. They set a “buy” rating and a $10.00 target price for the company. BidaskClub downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. ValuEngine upgraded Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Maxim Group set a $12.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $19.98.

Inovio Pharmaceuticals (NASDAQ INO) traded up 0.238% during midday trading on Thursday, reaching $6.305. The company had a trading volume of 1,392,495 shares. The stock’s market cap is $568.88 million. The firm has a 50-day moving average of $6.13 and a 200-day moving average of $6.65. Inovio Pharmaceuticals has a 12 month low of $5.28 and a 12 month high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.08. The business had revenue of $20.41 million during the quarter, compared to analysts’ expectations of $16.29 million. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The firm’s revenue for the quarter was up 229.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.26) earnings per share. On average, equities analysts expect that Inovio Pharmaceuticals will post ($0.92) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was reported by Markets Daily and is the property of of Markets Daily. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Insider Buying and Selling by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply